Spontaneous mutations in the single TTN gene represent high tumor mutation burden

Tumor mutation burden (TMB) is an emerging biomarker, whose calculation requires targeted sequencing of many genes. We investigated if the measurement of mutation counts within a single gene is representative of TMB. Whole-exome sequencing (WES) data from the pan-cancer cohort (n = 10,224) of TCGA, and targeted sequencing (tNGS) and TTN gene sequencing from 24 colorectal cancer samples (AMC cohort) were analyzed. TTN was identified as the most frequently mutated gene within the pan-cancer cohort, and its mutation number best correlated with TMB assessed by WES (rho = 0.917, p < 2.2e-16). Colorectal cancer was one of good candidates for the application of this diagnostic model of TTN-TMB, and the correlation coefficients were 0.936 and 0.92 for TMB by WES and TMB by tNGS, respectively. Higher than expected TTN mutation frequencies observed in other FLAGS (FrequentLy mutAted GeneS) are associated with late replication time. Diagnostic accuracy for high TMB group did not differ between TTN-TMB and TMB assessed by tNGS. Classification modeling by machine learning using TTN-TMB for MSI-H diagnosis was constructed, and the diagnostic accuracy was 0.873 by area under the curve in external validation. TTN mutation was enriched in samples possessing high immunostimulatory signatures. We suggest that the mutation load within TTN represents high TMB status.

[1]  Olaf Neumann,et al.  Size matters: Dissecting key parameters for panel‐based tumor mutational burden analysis , 2018, International journal of cancer.

[2]  Wyeth W Wasserman,et al.  FLAGS, frequently mutated genes in public exomes , 2014, BMC Medical Genomics.

[3]  Ahmet Zehir,et al.  Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Syed Haider,et al.  Ensembl BioMarts: a hub for data retrieval across taxonomic space , 2011, Database J. Biol. Databases Curation.

[5]  S. H. Wilson,et al.  Mammalian base excision repair by DNA polymerases delta and epsilon. , 1998, Oncogene.

[6]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[7]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[8]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[9]  Yassen Assenov,et al.  Maftools: efficient and comprehensive analysis of somatic variants in cancer , 2018, Genome research.

[10]  Jorge Sabbaga,et al.  Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice , 2015, Oncotarget.

[11]  Steven Henikoff,et al.  SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..

[12]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[13]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[14]  Hua Tan,et al.  Genome-wide mutational spectra analysis reveals significant cancer-specific heterogeneity , 2015, Scientific Reports.

[15]  Richard M. Simon,et al.  Using cross-validation to evaluate predictive accuracy of survival risk classifiers based on high-dimensional data , 2011, Briefings Bioinform..

[16]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[17]  M. Perucho,et al.  Microsatellite instability: The mutator that mutates the other mutator , 1996, Nature Medicine.

[18]  Conrad A. Nieduszynski,et al.  Genome-wide analysis of DNA replication timing in single cells: Yes! We’re all individuals , 2019, Genome Biology.

[19]  Tae Won Kim,et al.  Mutation Burden and I Index for Detection of Microsatellite Instability in Colorectal Cancer by Targeted Next-Generation Sequencing. , 2019, The Journal of molecular diagnostics : JMD.

[20]  C. Dang,et al.  Cancer genetics: Tumor suppressor meets oncogene , 1999, Current Biology.

[21]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[22]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[23]  Isabelle Salmon,et al.  Methods of measurement for tumor mutational burden in tumor tissue. , 2018, Translational lung cancer research.

[24]  Laurent Farinelli,et al.  Impact of replication timing on non-CpG and CpG substitution rates in mammalian genomes. , 2010, Genome research.

[25]  C. Jefford,et al.  Mechanisms of chromosome instability in cancers. , 2006, Critical reviews in oncology/hematology.

[26]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[27]  S. H. Wilson,et al.  Mammalian base excision repair by DNA polymerases δ and ε , 1998, Oncogene.

[28]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[29]  Li Ding,et al.  Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. , 2018, Cell systems.

[30]  K. Hess,et al.  Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. , 2011, JAMA.

[31]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[32]  Yi-Chen Yeh,et al.  Mutation load estimation model as a predictor of the response to cancer immunotherapy , 2018, npj Genomic Medicine.

[33]  S. Ramalingam,et al.  Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine? , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  F. Cunningham,et al.  The Ensembl Variant Effect Predictor , 2016, Genome Biology.

[35]  Richard Durbin,et al.  Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..